Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...

Children with MS who have more paramagnetic rim lesions, or chronic inflammation, tend to show faster declines in brain ...

The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.

Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t ...

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...

FLAMeS, a new convolutional neural network, enhances MS lesion segmentation accuracy using only T2-weighted FLAIR images, ...

Researchers report that elevated levels of the oral bacteria Fusobacterium nucleatum may be linked with greater disability in ...

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosisPERSEUS phase 3 study in primary progressive multiple sclerosis ...

Sanofi shares slide after FDA delays review of its MS drug tolebrutinib and a late-stage trial fails to meet its main goal.

If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to ...

Mendoza has used the spotlight of being a Heisman frontrunner to highlight his mother’s fight — he calls her his “light and ...

Indiana Hoosiers quarterback Fernando Mendoza just won the highly coveted Heisman Trophy, and in his acceptance speech he ...